Your browser is out-of-date!

Update your browser to view this website correctly.

To continue, please select your country of domicile and investor type. Depending on your domicile and the investor type that you select, you will have full or restricted access to the information due to legal reasons.

Retail clients: according to Art. 4 Abs. 2 FinSA

Professional/Institutional investors: according to Art. 4 paragraph 3-5 and Art. 5 paragraph 1 and 3-4 FinSA and Art. 10 paragraph 3 and 3ter CISA in conjunction with Art. 6a CISO



By using the website, you confirm that you have read, understood and accepted the general information provided by the Bellevue Group AG as well as these legal provisions. These may be subject to change and the use of the site may be restricted or terminated at any time without prior notice.

The information, products, data, services, tools and documents contained or described on this site ("website content") are for information purposes only and constitute neither an advertisement or recommendation nor an offer or solicitation (to buy) or redemption (sell) investment instruments, to effect any transaction or to enter into any legal relations.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.

In order to determine whether the investment in shares of a certain investment fund meets your specific requirements and matches your envisaged risks, we recommend that you contact an independent financial adviser. Furthermore, we recommend that you consult an independent tax adviser in order to obtain information on the tax regulations relating to a specific investment in your legal jurisdiction and with regard to your personal circumstances. In particular tax treatment depends on individual circumstances and may be subject to change.


Past performance is not an indication or guarantee of the future performance of the investment. The value of investments may be subject to fluctuations and, under certain circumstances, investors may not get back the full amount invested. Changes in foreign-exchange rates may also cause the value of investments to go up or down.

For a full explanation of risks and the overall risk profile of financial products mentioned on this site, please refer to the relevant Key Investor Information Documents (KIDs) and Prospectuses.


By accessing this website you state that you agree with the data protection statement. If you do not agree with this statement you should refrain from accessing any further pages of this website. This statement may be updated at any time. We therefore recommend that you check this statement regularly.


By clicking on "Accept", you confirm that you agree to the legal provisions. Alternatively, you can select "I don't accept" if you wish to leave the website

Board of Directors

  • Chairman


    Randeep Grewal

    Randeep Grewal is a London-based ex-Fund manager with over 17 years of Healthcare investment experience including at Trium, F&C Asset Management, ICAP Equities and Tudor. Randeep trained as a Vascular and General Surgeon and read both Medicine and Computer Science at Cambridge University.

  • Chair of the audit committee

    Chair of the audit committee

    Josephine Dixon

    Josephine Dixon is a chartered accountant who sits on the boards of JP Morgan European Growth & Income plc, Alliance Trust plc, Strategic Equity Capital plc and The Global Smaller Companies plc. Her executive experience includes finance, governance and general commercial roles in a number of sectors.

  • Member of the Board

    Member of the Board

    Kate Bolsover

    Kate Bolsover worked in the City of London for over 25 years, initially as an analyst and thereafter running the mutual fund businesses of both Baring Asset Management and Cazenove Fund Management. Latterly, she was appointed Director of Corporate Communications for JPMorgan Cazenove. Kate is Chairman of Fidelity Asian Values and is an independent director at Invesco Bond Income Plus, TR Property Investment Trust and Baillie Gifford & Co.

  • Member of the Board

    Member of the Board

    Prof. Tony Young

    Prof. Tony Young is a practicing frontline NHS surgeon, Associate Medical Director at the Mid and South Essex University Hospitals Group, Director of Medical Innovation at Anglia Ruskin University. In 2014 he was appointed as National Clinical Director for Innovation at NHS England and in February 2016 became the first National Clinical Lead for Innovation and played a leading role in coordinating the NHS response to the COVID-19 pandemic. In 2015 he founded the NHS Clinical Entrepreneur programme. In 2019 Tony was awarded the OBE for services to clinical leadership.

  • Member of the Board

    Member of the Board

    Paul Southgate

    Paul Southgate is a London-based Portfolio Manager at Pictet Asset Management, with over 21 years’ investment experience, including healthcare companies. Before joining Pictet, he was a Managing Partner at Eisenstat Capital Partners (ECAP) and managed European Equities for both Deephaven Capital and Fortress Investments Group. He began his career with UBS Asset Management.